重症冠心病急性心肌梗死患者治疗中应用瑞舒伐他汀与阿托伐他汀的临床价值

Clinical Value of Rosuvastatin and Atorvastatin in the Treatment of Pa⁃tients with Severe Coronary Heart Disease and Acute Myocardial Infarc⁃tion

目的研究重症冠心病急性心肌梗死患者治疗中应用瑞舒伐他汀与阿托伐他汀的临床价值。方法方便选择2020年1月—2021年1月到该院治疗的重症冠心病急性心肌梗死患者共98例作为研究对象,随机分为观察组与对照组,两组均给予常规基础治疗。对照组在此基础上接受瑞舒伐他汀治疗,观察组在对照组基础上加用阿托伐他汀治疗。分析两组患者临床治疗效果、心功能指标、炎症因子水平、血脂水平、不良反应出现概率、血压指标、NIHSS指标。结果观察组临床治疗效果48例(97.96%)高于对照组37例(75.51%),差异有统计学意义(χ^(2)=10.731,P<0.05);观察组患者心功能指标均优于对照组,差异有统计学意义(P<0.05);观察组患者炎症因子水平均低于对照组,差异有统计学意义(P<0.05);观察组患者血脂水平优于对照组,差异有统计学意义(P<0.05);观察组患者不良反应概率2.04%低于对照组6.12%,差异有统计学意义(P<0.05);观察组患者血压指标、NIHSS指标均高于对照组,差异有统计学意义(P<0.05)。结论运用瑞舒伐他汀药物与阿托伐他汀药物对重症冠心病急性心肌梗死患者治疗,在改善患者各项临床指标、提升疗效的同时,安全性也比较高。

Objective To study the clinical value of rosuvastatin and atorvastatin in the treatment of patients with se‐vere coronary heart disease and acute myocardial infarction.Methods A total of 98 patients with severe coronary heart disease and acute myocardial infarction who were treated in this hospital from January 2020 to January 2021 were conveniently selected as the research subjects and randomly divided into the observation group and the control group,both groups were given routine basic treatment.The control group received rosuvastatin treatment on this ba‐sis,and the observation group received atorvastatin treatment on the basis of the control group.The clinical treatment effect,cardiac function indexes,inflammatory factor levels,blood lipid levels,occurrence probability of adverse reac‐tions,blood pressure indexes,NIHSS indexes were analyzed in the two groups of patients.Results The clinical thera‐peutic effect of 48 cases(97.96%)in the observation group was significantly higher than that of 37 cases(75.51%)in the control group,the difference was statistically significant(χ^(2)=10.731,P<0.05);the indexes of cardiac function in the observation group were better than those in the control group,the difference was statistically significant(P<0.05);the levels of inflammatory factors in the observation group were significantly lower than those in the control group,the difference was statistically significant(P<0.05);the blood lipid level in the observation group was significantly higher than that in the control group,the difference was statistically significant(P<0.05);the probability of adverse reactions in the observation group was 2.04%lower than that in the control group 6.12%,and the difference was statistically significant(P<0.05);the indexes of blood pressure and NIHSS in the observation group were significantly higher than those in the control group,the difference was statistically significant(P<0.05).Conclusion The use of rosuvastatin and atorvastatin in the treatment of patients with severe coronary heart disease and acute myocardial infarction can improve the clinical indicators of patients and improve the efficacy,and at the same time,the safety is relatively high.